Verve Therapeutics Revenue vs. Shares Owned By Institutions

VERV Stock  USD 5.61  0.17  2.94%   
Based on Verve Therapeutics' profitability indicators, Verve Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Verve Therapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
11.8 M
Current Value
12.3 M
Quarterly Volatility
4.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Verve Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Days Of Sales Outstanding is likely to climb to 205.35 in 2024, whereas Price To Sales Ratio is likely to drop 72.28 in 2024. At this time, Verve Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Net Interest Income is likely to climb to about 22.4 M in 2024, despite the fact that Net Loss is likely to grow to (183.2 M).
For Verve Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Verve Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Verve Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Verve Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Verve Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.46)
Revenue Per Share
0.303
Quarterly Revenue Growth
1.202
Return On Assets
(0.22)
Return On Equity
(0.41)
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Verve Therapeutics Shares Owned By Institutions vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Verve Therapeutics's current stock value. Our valuation model uses many indicators to compare Verve Therapeutics value to that of its competitors to determine the firm's financial worth.
Verve Therapeutics is rated below average in revenue category among its peers. It is rated third in shares owned by institutions category among its peers . The ratio of Revenue to Shares Owned By Institutions for Verve Therapeutics is about  120,348 . At this time, Verve Therapeutics' Total Revenue is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Verve Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Verve Revenue vs. Competition

Verve Therapeutics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 1.36 Billion. Verve Therapeutics maintains roughly 11.76 Million in revenue contributing less than 1% to equities under Health Care industry.

Verve Shares Owned By Institutions vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Verve Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
11.76 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Verve Therapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
97.70 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Verve Shares Owned By Institutions Comparison

Verve Therapeutics is currently under evaluation in shares owned by institutions category among its peers.

Verve Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Verve Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Verve Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Verve Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Verve Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income272 K285.6 K
Net Interest Income21.3 M22.4 M
Interest Income7.9 M8.3 M
Operating Income-223.1 M-212 M
Net Loss-192.8 M-183.2 M
Income Before Tax-199.8 M-189.8 M
Total Other Income Expense Net23.3 M24.5 M
Net Loss-141.6 M-134.6 M
Net Loss-200.1 M-190.1 M
Income Tax Expense275 K288.8 K
Non Operating Income Net Other9.6 M10.1 M
Change To Netincome25.8 M27.1 M
Net Loss(3.12)(3.27)
Income Quality 0.75  0.54 
Net Income Per E B T 1.00  0.79 

Verve Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Verve Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Verve Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Verve Therapeutics' important profitability drivers and their relationship over time.

Use Verve Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Verve Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verve Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Verve Therapeutics Pair Trading

Verve Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Verve Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Verve Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Verve Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Verve Therapeutics to buy it.
The correlation of Verve Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verve Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verve Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Verve Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Verve Therapeutics position

In addition to having Verve Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Equity ETFs Thematic Idea Now

Broad Equity ETFs
Broad Equity ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.